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Abstract
Brugada syndrome is electrocardiographically characterised by ST segment elevation in right
precordial leads and the occurrence of episodes of polymorphic ventricular tachycardia. It is
also associated with a high risk of sudden death, which may be the first manifestation of the
disease. Various mutations of SCN5A gene encoding for the cardiac sodium channel are
among the proven causes of BS. ICD remains the only treatment for BS of proven efficacy.
However, many questions about etiology, underlying  mechanisms, safety of asymptomatic
patients and treatment options for BS remain unanswered. (Cardiol J 2007; 14: 429–435)
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Introduction
The term “Brugada syndrome” (BS), as a clin-
ical entity, was coined in 1992. It is now recognised
as the most common cause of genetically deter-
mined malignant ventricular arrhythmia and sudden
cardiac death in young patients with a structurally
normal heart. Patients with this syndrome present
with a characteristic electrocardiographic picture
consisting of elevated ST segments in the right
precordial leads which develop spontaneously or as
a result of drugs, fever or electrolyte imbalance.
Because, in some countries, BS is the second
most common cause of death in young adults, this
disease entity is generating increasing interest. This
article focuses on selected issues relating to the dis-
covery, pathogenesis, clinical picture, electrograph-
ic features and treatment of Brugada syndrome.
Discovery of the new disease entity
In 1953 an ECG was described which consist-
ed of ST segment elevation and T wave reversion
in the right precordial leads with or without right
bundle branch block. However, for over thirty years
this electrocardiographic phenomenon was not
linked to any specific clinical entity. Martini et al.
in 1989 and Aihara et al. [1] in 1990 started to asso-
ciate abnormalities in right ventricular repolarisa-
tion with sudden cardiac death. The Italian scien-
tists incorrectly associated them with anatomic
defects (with arrhythmogenic right ventricular dys-
plasia).
In 1986 the Brugada brothers described the
case of a 3-year-old boy, the son of Polish immi-
grants, who developed episodes of syncope, and
whose electrocardiogram revealed ST segment el-
evation limited to precordial leads V1–V3. The pa-
tient’s sister, who presented with similar clinical
and electrocardiographic manifestations, died at the
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age of 2 years [2]. Interestingly, the boy died sud-
denly at the age of 18 years at a disco, having al-
ready been implanted with an implantable cardio-
verter-defibrillator (ICD) (it is unknown whether
the death was caused by electrical storm or by
a failure of the cardioverter to fire).
By 1992, the authors had reported 8 such cas-
es, which formed the basis for proposing a new clin-
ical entity. The brothers maintained that the ECG
picture consisted of right bundle branch block and
ST segment elevation in V1–V3 even though the
signs of the bundle branch block were only present
in two of the eight reported electrocardiograms [2].
In 1996 Yan and Antzelevitch [3] established that
this was not a “true” right bundle branch block but
a “pseudo” right bundle branch block in which the
high elevation of the J point mimics the secondary
R wave in V1. However, the authority of the Brugada
brothers was so strong that for over 6 years the pres-
ence of right bundle branch block (RBBB) continued
to form the basis for ECG diagnosis. It was not until
the consensus report in 2002 that it was emphasised
that right bundle branch block may or may not be
present in the ECGs of patients with BS [4, 5].
Of note is the fact that a variant BS has been
reported in which ST segment elevation was ob-
served in inferior wall leads. It was demonstrated
to be associated with a new mutation of the SCN5A
gene [6].
Incidence of Brugada syndrome
Brugada syndrome most commonly manifests
in adulthood with the mean age of sudden death
being 41 ± 15 years (the youngest patient was
2 days old and the oldest was 84 years old) [4].
Brugada syndrome seems to account for 4–12%
of all cases of sudden death and approximately 20%
of deaths of patients without structural changes in
the myocardium. It is believed that in some coun-
tries, BS is the second most common cause of death
in the population of young adults after road traffic
accidents [4, 7].
The incidence of BS is estimated to be 5 cases
per 10,000 inhabitants [4]. However, the real inci-
dence of the disease in the general population is
difficult to ascertain for the following reasons: first-
ly, due to the dynamic nature of the ECG picture,
secondly, due to the more common occurrence of
type 2 and type 3 electrocardiograms, which do not
form the basis for diagnosis of BS and thirdly, and
possibly most importantly, due to insufficient
awareness of this electrocardiographic phenomenon
among doctors.
The relationship between sudden
unexpected nocturnal death syndrome
and Brugada syndrome
Research studies have confirmed previous sup-
positions that sudden unexpected nocturnal death
(SUND) syndrome and BS are phenotypically, geneti-
cally and functionally the same disease entity [7, 8].
Sudden unexpected nocturnal death syndrome has
been known in Southeast Asia and the Pacific Rim for
decades. It is known as “bangungut” in the Philip-
pines, “pokkuri” in Japan and “lai tai” in Thailand [8].
One report described 25 sudden deaths in one
family, 16 of which occurred during sleep. Of the
82 described cases of patients with SUND in
Southeast Asia, the age of the patients ranged from
16 to 63 years (mean, 32 years) and all but one
were male [8].
The three patterns of electrocardiographic
abnormalities in Brugada syndrome
The common feature of all three types of elec-
trocardiographic abnormalities seen in BS is
a J point elevation of at least 2 mm in two or three
right precordial leads (V1–V3) in the absence of
a known cause. The three patterns of ECG abnor-
malities in BS differ in terms of the nature of ST
segment elevation and the T wave morphology.
— type 1 is characterised by a convex (“lacunar”)
ST segment elevation of at least 2 mm followed
by a negative T wave (Fig. 1).
— type 2 is characterised by a concave (“sellar”)
ST segment elevation of at least 1 mm followed
by a positive or biphasic T wave (Fig. 1).
— type 3 is characterised by a concave ST seg-
ment elevation of less than 1 mm followed by
a positive T wave (Fig. 1).
While type 1 is diagnostic of BS, the electro-
cardiographic diagnosis in the case of types 2 and 3
requires a positive challenge test with a sodium
channel blocker (ajmaline, flecainide, procaina-
mide). The challenge test with ajmaline (1 mg/kg
IV) is considered positive if type 2 or type 3 con-
verts into type 1 and/or there is a J point elevation
of over 2 mm from baseline.
Clinical BS is diagnosed when type 1 electro-
cardiographic abnormalities are present in conjunc-
tion with at least one of the following criteria:
— documented ventricular fibrillation;
— documented polymorphic ventricular tachycardia;
— family history of sudden cardiac death before
45 years of age;
— recurrent syncope or nocturnal agonal respiration;
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— ECG abnormalities typical of BS among the pa-
tient’s relatives;




Brugada syndrome is inherited as an autosom-
al dominant trait of varying penetration. So far, the
only gene linked to BS is SCN5A, a gene encoding
for the alpha subunit of the cardiac sodium channel
[9, 10]. Over 80 mutations of this gene have been
discovered [4].
Analysis of the genetic background of BS draws
attention to three aspects. Firstly, SCN5A mutation
is also associated with type 3 congenital long QT
syndrome, which results in two different phenotypes
of sodium channel disease [11, 12]. Secondly, the
above mutation has only been proven in 15–30%
of BS cases. If so, what causes BS in the remaining
patients? Thirdly, despite the even distribution of
genetic transmission, the clinical phenotype is ob-
served 8 to 10 times more frequently in men than
in women. This is most probably due to the higher
intensity of the transient outward current (Ito) in
the right ventricular epicardium in men than in
women. This may result from a more rapid inacti-
vation of Ito channels in females or the difference
in their density between the sexes [13]. It is specu-
lated that the relative excess of the male phenotype
may be consequent to the role of testosterone [9].
Brugada syndrome has recently been linked to
another locus on chromosome 3, other than the
SCN5A locus. Brugada syndrome in this family tree
is characterised by progressive conduction abnor-
malities, weak response to procainamide and a rel-
atively good prognosis [14].
Brugada syndrome:
An “electrical” heart disease
Brugada syndrome is an “electrical” disease
caused by dysfunction of the characteristic ion chan-
nels. Studies have shown that in the overwhelm-
ing majority of patients, no structural substrate for
heart disease is present. Studies are, however, on-
going to establish the potential role of structural
abnormalities in the pathophysiology of this syn-
drome. Recently, Tagaki et al. [15] have used com-
puted tomography to demonstrate abnormalities of
myocardial contractility in the right ventricular out-
flow tract and in the inferior wall of the left ventri-
cle in 21 of 26 patients with BS. The studies have
shown that these abnormalities of contractility may
be associated with the abnormal shape of the action
potential in certain regions of the epicardium. The
limitation of calcium influx into the cells is thought
to be responsible for the loss of convexity in the
plateau phase of the action potential in subepicar-
dial regions of the right ventricle. Calcium content
in the sarcoplasmic reticulum is lower; therefore,
the contractility abnormalities are a reflection of
“electrical” rather than morphological changes in
the myocardium [15].
Is there any evidence to suggest a relationship
between BS and structural changes in the heart?
There has been a case report describing a patient
after a cardiac arrest with ECG abnormalities typi-
cal of BS, in whom magnetic resonance imaging
revealed signal hyperintensity in the left ventricu-
lar myocardium. Additional microscopic examina-
tion and polymerase chain reaction assay demon-
strated locally limited myocarditis caused by par-
vovirus B19. It is believed that local myocarditis
could have been the triggering factor of ventricular
arrhythmia in this patient [16].
Arrhythmogenic substrate in
patients with Brugada syndrome
The mechanism of ST segment elevation and
ventricular arrhythmias in patients with BS has not
Figure 1. Electrocardiogram of a patient with Brugada
syndrome. Precordial leads: the three different ECG pat-
terns: type 1 (left), type 2 (middle) and type 3 (right).
Arrows indicate ST segment elevation.
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been fully elucidated. Sodium channel dysfunction
is manifested by a lack of sodium channel expres-
sion, its underactivation or increased inactivation
[17]. The decrease of the inward sodium current
results in the domination of the Ito outward potas-
sium current. The Ito current is more active in the
epicardial cells than it is in the endocardium and the
M cells, which is most pronounced in the right ven-
tricle. This potential gradient at the end of phase
1 of the action potential is responsible for the high
J wave in the right precordial leads of the ECG.
The further course of the ECG curve depends on
the order of repolarisation events: If repolarisation
of the epicardium precedes repolarisation of the
M cells and endocardial cells, then the T wave re-
mains positive, but if the duration of the active
potential in the epicardium is prolonged, then the
direction of right ventricular wall repolarisation is
reversed (which means that the endocardial repo-
larisation precedes epicardial repolarisation), re-
sulting in the cup-like ST segment elevation and
T wave reversal, a typical Brugada-like pattern
(Fig. 2) [18].
The vast dispersion of repolarisation in the ep-
icardium and between the epicardium and endocar-
dium predisposes to phase 2 re-entry (through pre-
mature excitation during phase 2 of the action po-
tential). This is the triggering factor for polymorphic
tachycardia and ventricular flutter or fibrillation
[10, 18–21].
Factors predisposing to ECG signs
of Brugada syndrome and
associated arrhythmias
Several groups of factors triggering Brugada-type
ECG patterns and inducing polymorphic ventricular
tachycardia have been distinguished. These include:
— autonomic imbalance: Bradycardia may con-
tribute to triggering the arrhythmia. Japanese
scientists searched for the SCN5A gene muta-
tion in 38 unrelated patients with a clinical di-
agnosis of BS. The mutation was identified in
4 of 38 patients. All these patients had bradyar-
rhythmic complications: three were diagnosed
with sick sinus syndrome, and one was diag-
nosed with third-degree atrioventricular block.
It was hypothesised that patients with BS asso-
ciated with the SCN5A mutation were at high-
er risk of an episode of bradyarrhythmia than pa-
tients with SB but without this mutation [22];
— electrolyte imbalance: hypokalemia, hyper-
kalemia, hypercalcemia [4];
— fever: fever may trigger Brugada-type ECG
abnormalities, polymorphic tachycardia and
ventricular fibrillation [23, 24];
— myocardial ischemia: Recent myocardial in-
farction or vasospastic myocardial ischemia af-
fecting the right ventricular outflow tract mimic
ST segment elevation similarly to BS. This is
most likely a result of the decrease of the cal-
Figure 2. Diagrammatic representation of the action potential of the epicardial cells and the endocardial cells of the
right ventricle. A. Normal pattern; B. Brugada-type pattern.
A B
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cium channel current and the activation of the
ATP-dependent potassium channel during
ischemia, which suggests that patients with BS
may be more susceptible to sudden death if
ischemia coexists [4];
— drugs:
— antiarrhythmic drugs (sodium channel
blockers: class IA and IC, calcium antago-
nists: verapamil, beta-blockers),
— psychotropic drugs (tricyclic and tetracyclic
antidepressants, selective serotonin re-
uptake inhibitors),
— first generation antihistamines,
— alpha adrenergic agonists,
— potassium channel opening drugs,
— miscellaneous (toxic action of cocaine and
alcohol intoxication) [4, 25].
The above factors may occur in combination.
A case of transient Brugada-type ECG abnormalities
has been reported in a patient taking psychotropic
medication (with sodium channel blocking proper-
ties) with renal failure and hyperkalemia. The ECG
abnormalities resolved upon hemodialysis [26].
Identification of patients
at risk of sudden death
In light of the research studies conducted so
far, patients with aborted cardiac arrest have the
greatest risk of recurrence (69%), while in patients
with syncope and spontaneous signs of BS, the risk
is 19% [27].
Priori et al. [28] analysed a group of 200 patients
with BS. Based on the clinical, electrocardiograph-
ic and genetic characteristics, they distinguished
three groups of patients:
— group 1: high-risk group (10% of the study pop-
ulation) consisting of patients with a history of
syncope and ST segment abnormalities in rest-
ing ECG (cardiac arrest rate: 44%).
— group 2: intermediate-risk group (41% of the
study population) consisting of patients with-
out a history of syncope but with ST segment
abnormalities in resting ECG (cardiac arrest
rate: 14%).
— group 3: low-risk group (49% of the study pop-
ulation) consisting of patients with sodium
gene mutations and ECG abnormalities in-
duced in a drug challenge test (cardiac arrest
rate: 5%).
The prognostic and therapeutic approaches in
asymptomatic patients are controversial.
No prognostic markers have been identified in
asymptomatic patients. In a study of 30 asympto-
matic patients, a double SCN5A gene mutation was
demonstrated in most cases. It is believed that se-
vere sodium channel dysfunction, as a result of the
SCN5A gene mutation, is not the only factor caus-
ing the symptoms. Other unknown factors, which
may affect the prognosis, are postulated [29].
An interesting case of a 48-year-old asympto-
matic female with BS along with a retrospective
22-year analysis of ECG, Holter monitoring and
electrophysiological study (EPS) was reported in
“Kardiologia Polska”. The asymptomatic patient
without a family history of sudden cardiac death, ar-
rhythmic events or induced arrhythmia during EPS
qualified to the close observation group (she falls
within the intermediate-risk category according to
the stratification proposed by Priori et al.) [30].
The importance of ECG studies
in patients with electrocardiographic
features of Brugada syndrome (in
accordance with ESC recommendations)
There is controversy as to the importance of
electrophysiological studies (EPS) in asymptomat-
ic patients. Brugada et al. [31] demonstrated a re-
lationship between the triggering of VT/VF and the
risk of sudden death, which has not been confirmed
in other studies [28, 32]. The possible causes of this
discrepancy may include differences in stimulation
protocols or in the duration of follow-up.
According to the current European Society
of Cardiology (ESC) guidelines, EPS may be con-
sidered to estimate the risk in patients with asymp-
tomatic BS with spontaneous ST segment elevation
with or without the SCN5A gene mutation (Class
IIb, Level C) [33].
Genetic analysis in Brugada syndrome
According to current opinion, genetic analysis has
no role in the estimation of risk in BS. Nevertheless,
it may help to identify asymptomatic carriers of the
mutation, who may then be provided with clinical
monitoring and genetic counselling [33].
In an article recently published in “Folia Car-
diologica” reporting a 40-year-old symptomatic pa-
tient with a family history of sudden deaths, the
possibility has been pointed out of performing ge-
netic testing for BS (using the polymerase chain
reaction) courtesy of Dr Ramon Brugada (New York
Heart Center), thanks to which a mutation of
SCN5A exon 27 has been detected, and an identi-
cal mutation has been detected in the patient’s
17-year-old son [34].
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Treatment of Brugada syndrome
The only proven treatment option for BS is an
ICD. According to the current ESC guidelines, im-
plantation of an ICD is indicated for patients with
BS and aborted cardiac arrest who receive optimal
long-term treatment and whose life expectancy in
good general condition exceeds one year (Class I,
Level C). Implantation of an ICD is justified in pa-
tients with BS and:
— spontaneous ST segment elevation in V1–V3,
with a history of syncope with or without the
SCN5A gene mutation and whose life expectan-
cy in good general condition exceeds one year.
— documented VT which did not lead to cardiac ar-
rest, whose life expectancy in good general con-
dition exceeds one year (Class IIa, Level C) [33].
Alternative treatments
for Brugada syndrome
A potential role of pacemakers in the treatment
of BS has been suggested because arrhythmias and
sudden cardiac death occur more frequently during
sleep or at rest, two states associated with brady-
cardia. However, the role of cardiac stimulation in
the treatment of BS remains to be investigated [17].
The idea of drug treatment rests on the as-
sumption that balancing the active currents during
early phases of the action potential in the right ven-
tricular epicardium will restore the normal doming
of the action potential. Because it is believed that
the considerable outward current (Ito) is an under-
lying cause of BS, all agents that block this type of
current may have cardioprotective effects. Unfor-
tunately, no selective blockers of the outward cur-
rent Ito are available. Quinidine remains the only
agent that effectively restores the normal doming
of the action potential (and normalises the ST seg-
ment) and prevents polymorphic ventricular tachy-
cardia. It inhibits the Ito current and has been shown
to normalise effectively ST segment elevation in
patients with BS. According to ESC guidelines, ad-
ministration of quinidine may be justified in the
treatment of electrical storm in patients with BS
(Class IIb, Level C).
It is believed that drugs that increase the cal-
cium current (such as isoproterenol) may also prove
therapeutically effective [4]. Isoproterenol is rec-
ommended in the treatment of electrical storm
(Class IIa, Level C) [33].
Cilostazol, a phosphodiesterase III inhibitor, is
a new addition to the pharmacological arsenal.
It normalises the ST segment by reducing the Ito
current and increasing the calcium current. Tedis-
amil is an investigational antiarrhythmic agent with
a potential inhibitory effect on the Ito current [4].
An ideal drug would consist of a cardioselec-
tive and Ito-selective blocker, especially for use in
newborns and those adults for whom an ICD is un-
reachable.
Summary
Brugada syndrome is electrocardiographically
characterised by ST segment elevation in right pre-
cordial leads and the occurrence of episodes of poly-
morphic ventricular tachycardia. It is also associated
with a high risk of sudden death, which may be the
first manifestation of the disease. Various mutations
of SCN5A gene encoding for the cardiac sodium chan-
nel are one of the proven causes of BS. ICD remains
the only treatment for BS of proven efficacy.
Many questions about BS remain unanswered,
such as:
— What is the etiology of the majority of cases of
BS? (Genetic defects undetected so far? Per-
haps these are acquired forms?)
— Is the dispersion of repolarisation the only fac-
tor responsible for electrical instability of the
ventricles in these patients?
— Can poor prognostic markers be identified in
asymptomatic patients?
— Can patients with BS be effectively managed
pharmacologically?
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